Joseph Pantginis, an analyst from H.C. Wainwright, reiterated the Buy rating on Travere Therapeutics. The associated price target remains the same with $47.00.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Joseph Pantginis has given his Buy rating due to a combination of factors surrounding Travere Therapeutics’ recent advancements with their drug FILSPARI. The company has effectively addressed previous concerns from the DUPLEX study by demonstrating that FILSPARI’s ability to reduce proteinuria is linked to long-term clinical benefits for patients with FSGS. This was achieved through the PARASOL initiative, which validated a urine protein-to-creatinine ratio threshold that serves as a meaningful surrogate for kidney protection.
Moreover, new analyses presented at the ASN Kidney Week 2025 showed that FILSPARI-treated patients reached significant proteinuria reduction levels more frequently and earlier than those on alternative treatments. These findings suggest a substantial reduction in the risk of kidney failure over a five-year period, reinforcing the drug’s potential benefits. The data indicates that FILSPARI’s proteinuria reduction translates into a meaningful decrease in long-term kidney failure risk, supporting the positive outlook for Travere’s stock.
Pantginis covers the Healthcare sector, focusing on stocks such as Lexicon Pharmaceuticals, Celldex, and Iovance Biotherapeutics. According to TipRanks, Pantginis has an average return of 2.2% and a 44.09% success rate on recommended stocks.
In another report released on November 4, Bank of America Securities also maintained a Buy rating on the stock with a $39.00 price target.